Simavita Limited Annual Report 2020

Board of Directors MICHAEL SPOONER Executive Chairman Mr Spooner was appointed as Non Executive Chairman of Simavita in May 2016 and in July 2019 became Executive Chairman. Mr Spooner has also served on the Board of Directors of Mesoblast since 2004. During this period he has filled various roles including as Executive Chairman from the date of the ASX public listing in 2004 until 2007. He is currently a member of Simavita’s Audit and Risk Committee and the Remuneration Committee. He is also the Chairman of MicrofluidX since February 2018. Over the past several years Mr Spooner has served on the Board of Directors in various capacities at several Australian and international biotechnology companies, including BiVacor Pty Ltd (2009-2013), Advanced Surgical Design & Manufacture Limited (2010-2011), Peplin, Inc. (2004-2009), Hawaii Biotech, Inc. (2010-2012), Hunter Immunology Limited (2007- 2008), and as managing director of Ventracor Limited (2001- 2003). Prior to returning to Australia in 2001, he spent much of his career internationally where he served in various roles including as a partner to PA Consulting Group, a United Kingdom-based management consultancy and a Principal Partner and Director of Consulting Services with PricewaterhouseCoopers (Coopers & Lybrand) in Hong Kong. In addition, Mr Spooner has owned and operated several international companies providing services and has consulted to a number of American and Asian public companies. DR GARY W PACE Non-Executive Director Dr Pace has more than 40 years of experience in the development and commercialization of advanced life sciences and related technologies, spanning biotechnology, pharmaceuticals, medical devices, and food industries. He is a serial entrepreneur and has held senior positions in small to and large-scale life sciences ventures and companies in Australia, the USA and Europe. Dr Pace has contributed to the development of the biotechnology industry through honorary university appointments and industry and government committees. He is currently a member of the Audit and Risk Committee and the Remuneration Committee. Dr. Pace is currently a Director of two public companies; Pacira Pharmaceuticals Inc (NASDAQ: PCRX); and Antisense Therapeutics (ASX: ANP) as well as several private companies. He recently retired from ResMed (NYSE, RMD) after serving as a Director for 24 years. Dr. Pace holds a B.Sc. (Hons I) from the University of New South Wales and a Ph.D. from the Massachusetts Institute of Technology. Also he has held visiting academic positions at the Massachusetts Institute of Technology and the University of Queensland. Dr. Pace is an elected Fellow of the Australian Academy of Technological Sciences and Engineering. DAMIAN HAAKMAN Non-Executive Director Mr Haakman was appointed Non-Executive Director of Simavita in 2018. Mr Haakman is the Managing Director of a private family office. He manages a portfolio including commercial property, property development joint ventures, mezzanine finance and bridging loans as well as investments in start-up and pre-listed companies. Damien’s background includes; due diligence work, forecasting, market assumptions and trends. He has a keen interest and is following the growing wearable technology space as well as Connected Devices (Internet of Things (IoT), Smart Devices, Mobile Apps). He is currently a member of the Audit and Risk Committee and the Remuneration Committee. Mr Haakman was previously a Director of Simavita Holdings Limited from 2012 until February 2016 and a Director of Simavita Limited from the time of its ASX listing in November 2013 until 2016. Mr Haakman is a member of the Australian Institute of Company Directors. ALAN D. FISHER Non-Executive Director Mr Fisher was appointed to the Board on July 22, 2019. Mr Fisher is the Managing Director of Fisher Corporate Advisory. He has extensive experience as a corporate advisor and professional director specialising in M&A, strategic advice, business restructurings and capital raisings. Previously he spent 24 years at global accounting firm Coopers & Lybrand where he headed and grew the Melbourne Corporate Finance Division. He is a fellow of the Institute of Chartered Accountants ANZ and a member of the Australian Institute of Company Directors. Mr Fisher is Chair of Simavita’s Audit and Risk Committee. He is currently Non- Executive Chair of Centrepoint Alliance Limited and IDT Australia Limited and Non-Executive Director and Chair of the Audit and Risk Committee of Thorney Technologies Limited and Bionomics Limited. Simavita Limited 8